Day: May 14, 2021

SEATTLE, May 14, 2021 (GLOBE NEWSWIRE) — Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in oncology and infectious disease with a current focus on breast cancer and COVID-19, today announces financial results for the fiscal quarter ended March 31, 2021, and provides an update on recent company developments. Key developments from Q1 2021 and to date include:Atossa concluded its open-label Phase 2 clinical study of oral Endoxifen administered in the “window of opportunity” between diagnosis of breast cancer and surgery based on positive results allowing acceleration of the Endoxifen program in the United StatesAnnounced updated findings following 24 months of an Expanded Access (or “compassionate use”) single-patient study of Endoxifen...

Underwriters’ Full Exercise of Option Brings Gross Proceeds to $34.5 Million EXTON, Pa., May 14, 2021 (GLOBE NEWSWIRE) — Recro Pharma, Inc. (“Recro”; NASD:REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid dose drug products, today announced the closing of its previously announced underwritten public offering of 15,333,332 shares of its common stock, including 1,999,999 shares sold pursuant to the underwriters’ full exercise of their option to purchase additional shares to cover over-allotments, at a public offering price of $2.25 per share. The gross proceeds to Recro from this offering are approximately $34.5 million, before underwriting discounts and commissions and estimated offering expenses.   Recro intends...

The Annual General Meeting of Shareholders of AB „Rokiškio sūris“ (company code 173057512, address Pramonės str.3, Rokiškis), which took place on 30 April 2021, decided to allocate EUR 0.10 per share for 2020 (the total amount of dividends for 2020 is EUR 3.501 million). Dividends will be paid to those persons who at the end of the tenth business day following the General Meeting of Shareholders accepting the payment of dividends, i.e. May 14, 2021 will be shareholders of AB Rokiškio sūris. As of May 26, 2021, dividends will be paid in the following order:For shareholders whose bookkeeping of AB Rokiškio sūris shares is managed by financial brokerage firms or branches of credit institutions providing securities accounting services, the amount of dividends after deduction of personal income tax or income tax under the laws of the Republic...

SEATTLE, May 14, 2021 (GLOBE NEWSWIRE) — Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases, today announced that management will participate at the Investor Summit Conference on May 18, 2021. CEO Dr. Steven Quay and Kyle Guse, CFO and General Counsel will deliver a corporate presentation at 8:45am ET on May 18, 2021. Investors can also request a one-on-one meeting with management to be arranged following the conclusion of the conference. Investors can register for the conference here. About Atossa Therapeutics Atossa Therapeutics, Inc. (Nasdaq: ATOS) is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant...

CALGARY, Alberta, May 14, 2021 (GLOBE NEWSWIRE) — DIVERGENT Energy Services Corp. (“Divergent”, the “Company”, or “DVG”) is pleased to announce the appointment of Ken Olson as Interim Chief Financial Officer of the Company, effective May 17, 2021, replacing Lance Mierendorf who has chosen to leave the Company to pursue another opportunity, effective May 15, 2021. Mr. Olson has over 28 years of finance and accounting experience, including 12 years in executive leadership positions within the oilfield services sector. In these roles he provided executive leadership with equity financing, acquisitions & divestitures, corporate restructurings, corporate governance, and building global finance teams. Prior thereto, Ken spent 6 years with a technology company in numerous positions and 12 years with PricewaterhouseCoopers. Ken Berg,...

FLORHAM PARK, N.J., May 14, 2021 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the company will participate and be available for 1×1 meetings at the following upcoming conference:Oppenheimer Rare & Orphan Disease SummitDate: May 21, 2021Time: On demand presentation for registered participants  Available for 1×1 meetingsWebcast: To register, click on the link HEREA replay of the presentation will be available on the Events page of the company website. About Cellectar Biosciences, Inc.Cellectar Biosciences is focused on the discovery and development of drugs for the treatment of cancer. The company is developing proprietary drugs independently...

LAKEWOOD, N.J., May 14, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Reliance Global Group, Inc. (Nasdaq: RELI; RELIW), which combines AI and cloud-based technologies with the personalized experience of a traditional insurance agency, today provided a business update and reported financial results for the first quarter ended March 31, 2021. Ezra Beyman, CEO of Reliance Global Group, commented, “We continue to execute on our organic growth strategy as evidenced by a 15% increase in revenue for the first quarter of 2021 over the same period last year.  I am also pleased to report that we continue to increase the cash flow from our insurance operations.   We ended the quarter with over $10 million of cash and restricted cash, which provides us a solid balance sheet to execute on our near and long-term growth objectives.  At the...

CAMBRIDGE, Mass., May 14, 2021 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal imbalance, today announced that management will participate in the following upcoming virtual investor conferences:RBC Capital Markets Global Healthcare ConferencePresentation on Wednesday, May 19, 2021 at 2:30 p.m. ETOppenheimer Rare & Orphan Disease SummitPrerecorded presentation available on Friday, May 21, 2021 at 8:00 a.m. ETThe events will be available via webcast through the Events & Presentations page of the Investors + Media section of the company’s website at www.praxismedicines.com. Replays of the webcasts will be available for 90...

DALLAS, Texas, May 14, 2021 (GLOBE NEWSWIRE) — HXPN, Inc. (OTCQB: HXPN), an emerging technologies and mineral resources development company, today announced that Stephen (Steve) L. Bailey has been named as Chairman of the Board, President and Chief Executive Officer, as well as interim Chief Financial Officer. Mr. Bailey’s employment with HXPN commenced on May 10, 2021. He was a consultant to the Company for several months prior to his employment. HXPN, Inc., also known as Harris Exploration Inc., a Nevada corporation, has been inactive for the last several years while the Board searched for a new CEO to lead and establish a vision and direction for the Company. The Company will continue its historic focus on mineral resources development and will also pursue investments in emerging technologies. Bailey has more than 12 years of...

Hamilton, Bermuda, May 14, 2021 Flex LNG Limited (“Flex LNG” or the “Company”) will release its preliminary financial results for the first quarter of 2021 on Friday May 21, 2021 on or about 7:00 a.m. CET (1:00 a.m. EST). In connection with the earnings release, a webcast and conference call will be held at 2:00 p.m. CET (8:00 a.m. EST). In order to attend the webcast and/or conference call you may do one of the following: Attend by Webcast: Use to the follow link prior to the webcast: https://edge.media-server.com/mmc/p/gx66qkea    Attend by Conference Call: Applicable dial-in telephone numbers are as follows: Norway: +47 21 03 39 22 United Kingdom: +44 (0) 203 0095709United Kingdom, local: 0844 4936 766United States: +1 646 787 1226United States (toll free): +1 866 2801 157 Confirmation Code: 7896598 A Q&A...